Back to top
more

Arvinas (ARVN)

(Delayed Data from NSDQ)

$27.14 USD

27.14
840,209

-0.61 (-2.20%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $27.18 +0.04 (0.15%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas (ARVN) delivered earnings and revenue surprises of 22.73% and 45.09%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Novartis' (NVS) Motion to Block Entresto Generic Denied: What's Next?

by Zacks Equity Research

Novartis' (NVS) efforts to ward off generic competition for its top cardiovascular drug, Entresto, face a setback.

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas (ARVN) delivered earnings and revenue surprises of 31.94% and 20.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Novartis (NVS) Tops on Q2 Earnings, Ups Operating Income View

by Zacks Equity Research

Novartis' (NVS) second-quarter earnings and sales beat estimates. Based on strong momentum, the company raises its operating income outlook for 2024.

Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Arvinas (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Cytek Biosciences (CTKB) Moves 5.1% Higher: Will This Strength Last?

by Zacks Equity Research

Cytek Biosciences (CTKB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Acadia (ACHC), Geisinger JV Begin Construction of New Hospital

by Zacks Equity Research

The new hospital from Acadia (ACHC) and Geisinger JV is scheduled to open in spring 2025.

Absci (ABSI) to Report Q1 Earnings: Here's What to Expect

by Zacks Equity Research

The focus is likely to be on progress on its pipeline candidates when generative AI drug creation company Absci (ABSI) reports first-quarter results.

Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Arvinas (ARVN) delivered earnings and revenue surprises of 34.46% and 18.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for Arvinas (ARVN)

by Zacks Equity Research

Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline

by Zacks Equity Research

Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

by Zacks Equity Research

Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novartis (NVS) Q1 Earnings, Sales Beat, Guidance Raised

by Zacks Equity Research

Novartis (NVS) comfortably beats first-quarter earnings and sales estimates. The company ups its outlook for 2024 on strong growth across key brands.

Novartis (NVS) Inks Deal for ARVN's Prostate Cancer Candidate

by Zacks Equity Research

Novartis (NVS) enters into a license deal with Arvinas, Inc. (ARVN) for the worldwide development and commercialization of cancer candidate ARV-766. Shares of ARVN rise on the news.

Kaibalya Pravo Dey headshot

Is Arvinas (ARVN) Stock a Solid Choice Right Now?

by Kaibalya Pravo Dey

Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?

by Zacks Equity Research

Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -90.23% and 210.76%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street Analysts See a 30.21% Upside in Arvinas, Inc. (ARVN): Can the Stock Really Move This High?

by Zacks Equity Research

The consensus price target hints at a 30.2% upside potential for Arvinas, Inc. (ARVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Arvinas, Inc. (ARVN) have what it takes to be a top stock pick for momentum investors? Let's find out.

Can Tenet's (THC) Q4 Earnings Beat on Rising Patient Admissions?

by Zacks Equity Research

Tenet's (THC) fourth-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.

Wall Street Analysts Think Arvinas, Inc. (ARVN) Could Surge 26.67%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 26.7% in Arvinas, Inc. (ARVN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Encompass Health (EHC) to Post Q4 Earnings: What's in Store?

by Zacks Equity Research

Encompass Health's (EHC) fourth-quarter results are likely to reflect pricing increases and growing volumes.

Arvinas, Inc. (ARVN) Soars 10.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Arvinas, Inc. (ARVN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Will High Medical Costs Affect Centene's (CNC) Q4 Earnings?

by Zacks Equity Research

Centene's (CNC) fourth-quarter results are likely to reflect growth in premiums and overall memberships.